Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In response the novel coronavirus emergency, the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) has activated its Clinical Characterisation Protocol (CCP) for emerging infections in England and Scotland.

Coronavirus © Alissa Eckert, MS; Dan Higgins, MAM

The Clinical Characterisation Protocol (CCP) was prepared for just such an emergency. It provides an ethically approved framework for enrolling patients to a clinical study which will offer new insights into this emerging global threat.

The CCP facilitates the collection of standardised clinical data and samples on patients hospitalised with suspected or confirmed infection with novel coronavirus. This will inform the outbreak response and patient care, not just in the UK but internationally. With novel coronavirus patients now identified in the UK, the UK health research community is well-prepared to advance our understanding of this disease.

The Chief Investigator for the UK CCP is Professor Calum Semple at the University of Liverpool. The development of the CCP was led by Dr Kenneth Baillie at the University of Edinburgh. The CCP study is sponsored by the University of Oxford and ISARIC’s Global Support Centre is hosted by the University of Oxford. ISARIC’s Members have developed the CCP over a number of years.

The CCP is supported by the National Institute for Health Research (NIHR) and is now open to enrolment in NHS Trusts, including the network of high-containment clinical facilities where patients with novel coronavirus will be admitted in the early stages of the disease in the UK.

ISARIC logoISARIC is a global federation of clinical research networks, providing a proficient, coordinated, and agile research response to outbreak-prone infectious diseases. ISARIC’s mission is to generate and disseminate clinical research evidence for outbreak-prone infectious diseases, whenever and wherever they occur.

ISARIC is funded by the Wellcome Trust, the UK Department for International Development, and the Bill & Melinda Gates Foundation.

Similar stories

RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

Professors Peter Horby and Guy Thwaites recognised in Queen’s Birthday Honours

The pioneering work of members of the University of Oxford has been recognised in The Queen's Birthday Honours List. The honorands include Professor Peter Horby and six researchers that have played key roles in leading the University’s response to the Coronavirus pandemic, from the development of new vaccines to the discovery of new drug treatments. Professor Guy Thwaites is appointed a Member of the Order of the British Empire.

RECOVERY trial finds aspirin does not improve survival for patients hospitalised with COVID-19

The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for patients hospitalised with COVID-19. Patients with COVID-19 are at increased risk of blood clots forming in their blood vessels, particularly in the lungs. Between November 2020 and March 2021, the RECOVERY trial included nearly 15,000 patients hospitalised with COVID-19 in an assessment of the effects of aspirin, which is widely used to reduce blood clotting in other diseases. There was no significant difference in the primary endpoint of 28-day mortality

The COVID-19 International Modelling Consortium (CoMo Consortium) enters a new phase

Created in March 2020 to assist policymakers to make use of existing evidence in mathematical and epidemiological models to inform strategies for minimising the impact of COVID-19, the CoMo Consortium brings together mathematical modellers, epidemiologists, health economists and public health experts from more than 40 countries across Africa, Asia and South and North America.

New Pandemic Sciences Centre at the University of Oxford

The University of Oxford announces the launch of a centre of global research collaboration and excellence, the Pandemic Sciences Centre. The need for partnership between academic excellence, industry and public health organisations is one of the key lessons learned from the coronavirus pandemic. This centre will unite disciplines, and sectors, to build agile, equitable partnerships that can tackle complex problems and respond to pandemic threats at any time.

RECOVERY trial named David Sackett Trial of the Year 2020

The RECOVERY trial has been named David Sackett Trial of the Year by the Society for Clinical Trials. The award was presented today at the Society for Clinical Trials’ 42nd Annual Meeting.